<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03032562</url>
  </required_header>
  <id_info>
    <org_study_id>KSN_2016_2_MB</org_study_id>
    <nct_id>NCT03032562</nct_id>
  </id_info>
  <brief_title>Respiratory Muscle Strength and Function in Neuromuscular Disorders and Chronic Obstructive Pulmonary Disease</brief_title>
  <official_title>Multimodal Measurement of Respiratory Muscle Strength and Function: Validation of Volitional and Non-volitional Tests With Regard to Nocturnal Hypoventilation in Patients With Neuromuscular Disorders and Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Westfälische Wilhelms-Universität Münster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Westfälische Wilhelms-Universität Münster</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Using an extensive set of both volitional and non-volitional tests of respiratory muscle&#xD;
      function and strength it is the aim of this study to&#xD;
&#xD;
        -  identify disease-specific patterns of respiratory muscle impairment in different NMD and&#xD;
           COPD&#xD;
&#xD;
        -  establish which set of tests is predictive of sleep-disordered breathing or daytime&#xD;
           hypercapnia in patients with NMD or COPD, respectively.&#xD;
&#xD;
        -  to investigate the decline of respiratory muscle function in patients with progressive&#xD;
           NMD and COPD along with sleep studies and capnography&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous neuromuscular disorders (NMD) are characterized not only by weakness of axial and&#xD;
      limb muscles but also by respiratory muscle and upper airway involvement. Respiratory muscle&#xD;
      weakness first manifests as sleep-disordered breathing (SDB). SDB in neuromuscular disease&#xD;
      mainly comprises alveolar hypoventilation but upper airway collapse may also occur because&#xD;
      pharyngeal muscle tone is impaired by both neuromuscular weakness and sleep.&#xD;
&#xD;
      Diaphragmatic weakness and myopathy are hallmarks of advanced obstructive pulmonary disease&#xD;
      leading to even greater impairment of gas exchange in affected patients.&#xD;
&#xD;
      Non-invasive ventilation (NIV) should be initiated in patients with diaphragm weakness if&#xD;
      significant SDB or hypercapnic respiratory failure is present. Indication criteria for NIV&#xD;
      include measurement of spiromanometric parameters such as forced vital capacity (FVC),&#xD;
      maximum inspiratory pressure (MIP), or sniff nasal inspiratory pressure (SNIP). These&#xD;
      measurements are volitional, i. e. test results are dependent on individual patient effort&#xD;
      and may show intraindividual variance which may not properly reflect disease progression or&#xD;
      treatment effects, respectively. Associations between volitional and non-volitional methods&#xD;
      of respiratory muscle strength testing have been reported mainly for healthy individuals but&#xD;
      only scarcely in patients with specific NMD.&#xD;
&#xD;
      Non-volitional tests of respiratory muscle strength include phrenic nerve conduction studies,&#xD;
      diaphragmatic ultrasound, and magnetic stimulation of the phrenic nerves in particular.&#xD;
      Magnetic stimulation is usually combined with esophageal and gastric manometry yielding the&#xD;
      twitch transdiaphragmatic pressure which closely reflects diaphragmatic strength.&#xD;
&#xD;
      It is desirable to obtain validated data on both volitional and non-volitional tests of&#xD;
      respiratory muscle strength in various NMD. Validation has to be carried out with regard to&#xD;
      both daytime hypercapnia and nocturnal retention of carbon dioxide because the latter often&#xD;
      represents the earliest manifestation of respiratory muscle weakness. SDB often starts long&#xD;
      before exertional dyspnea or orthopnea develop. Since NIV is one of the mainstays of&#xD;
      symptomatic treatment in both NMD and advanced obstructive lung disease, early recognition of&#xD;
      SDB is crucial for optimal patient care, and in many conditions, life expectancy and quality&#xD;
      of life may be substantially increased by NIV. In this study, FVC, MIP, MEP and SNIP testing&#xD;
      along with non-volitional methods and diaphragmatic ultrasound will be applied in order to&#xD;
      establish a protocol which may help to reliably predict SDB or need for ventilatory support,&#xD;
      respectively.&#xD;
&#xD;
      Patients with chronic obstructive pulmonary disease (COPD) develop flattening, shortening,&#xD;
      and weakness of the diaphragm. This is not only due to downward dislocation of the diaphragm&#xD;
      but also to impairment of contractile function, tissue structure, and intracellular&#xD;
      biochemistry. Respiratory muscle weakness in COPD is of major clinical relevance since&#xD;
      maximum inspiratory pressure is an independent predictor of survival in severely affected&#xD;
      patients. In addition, hypercapnic respiratory failure due to inspiratory muscle weakness is&#xD;
      associated with morbidity and mortality in COPD.&#xD;
&#xD;
      Direct comparison of both volitional and non-volitional measures of respiratory muscle&#xD;
      function between patients with diaphragmatic weakness due to neuromuscular disease and&#xD;
      patients with COPD is desirable. This approach may allow for further characterization of&#xD;
      &quot;impairment patterns&quot; probably specific to either COPD or certain neuromuscular disease,&#xD;
      respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">December 1, 2016</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of daytime hypercapnia</measure>
    <time_frame>1 day</time_frame>
    <description>paCO2 &gt; 45 mmHg</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence of sleep-disordered breathing</measure>
    <time_frame>1 day</time_frame>
    <description>nocturnal tcCO2 &gt; 50 mmHg, delta tcCO2 &gt; 10 mmHg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>twitch transdiaphragmatic pressure</measure>
    <time_frame>1 day</time_frame>
    <description>difference between intraesophageal and intragastral pressure after posterior magnetic stimulation of the phrenic nerves</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Respiratory Muscle Paralysis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Patients with neuromuscular disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Patients with chronic obstructive pulmonary disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Multimodal measurement of respiratory muscle function and strength</intervention_name>
    <description>Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known neuromuscular disease and individuals with chronic obstructive&#xD;
        pulmonary disease (and no neuromuscular disorder)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with NMD (n=100): Amyotrophic lateral sclerosis, Pompe's disease, myotonic&#xD;
             dystrophy type 1, limb-girdle muscular dystrophies, spinal muscular atrophy, etc.&#xD;
&#xD;
          -  patients with chronic obstructive lung disease (n=100)&#xD;
&#xD;
          -  age 18 - 80 years&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  significant chest wall deformity&#xD;
&#xD;
          -  tracheostomy&#xD;
&#xD;
          -  inability to sit in the upright position&#xD;
&#xD;
          -  impaired consciousness&#xD;
&#xD;
          -  acute or severe medical comorbidity&#xD;
&#xD;
          -  mechanical ventilation for more than 4 hours during daytime&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Matthias Boentert, MD</last_name>
    <phone>+49-251-83</phone>
    <phone_ext>44458</phone_ext>
    <email>matthias.boentert@ukmuenster.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Young, MD</last_name>
    <phone>+49-251-83</phone>
    <phone_ext>48196</phone_ext>
    <email>peter.young@ukmuenster.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Münster, Department of Sleep Medicine and Neuromuscular Disorders</name>
      <address>
        <city>Munster</city>
        <state>NRW</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Boentert, MD</last_name>
      <phone>+49-251-83</phone>
      <phone_ext>44458</phone_ext>
      <email>matthias.boentert@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Boentert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethanien Hospital</name>
      <address>
        <city>Solingen</city>
        <state>NRW</state>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Winfried Randerath, MD</last_name>
      <phone>+49-212</phone>
      <phone_ext>636000</phone_ext>
      <email>winfried.randerath@klinik-bethanien.de</email>
    </contact>
    <contact_backup>
      <last_name>Simon Herkenrath, MD</last_name>
      <phone>+49-212</phone>
      <phone_ext>636000</phone_ext>
      <email>simon-dominik.herkenrath@klinik-bethanien.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>January 24, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Westfälische Wilhelms-Universität Münster</investigator_affiliation>
    <investigator_full_name>Matthias Boentert</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>respiratory muscle strength</keyword>
  <keyword>sleep-disordered breathing</keyword>
  <keyword>neuromuscular disease</keyword>
  <keyword>chronic-obstructive pulmonary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Respiratory Paralysis</mesh_term>
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

